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Introduction
Angiogenesis, the outgrowth of new from preexisting blood ves-
sels, is an important pathogenic aspect of tumor growth, chronic
inflammatory diseases, and most blinding ocular conditions (for
review see ref. 1). To clearly separate it from the process of lym-
phangiogenesis, we will refer to blood vascular angiogenesis as
hemangiogenesis (HA). In recent years, much has been learned
about the stimulators and inhibitors of HA and lymphangiogen-
esis, and members of the VEGF family have emerged as prime
mediators of both processes (for review see refs. 2–4). The VEGF
growth factor family consists of five members that bind to and
activate three distinct receptors. VEGF-A binds to VEGFR1 and
VEGFR2, and placental growth factor (PlGF) and VEGF-B bind
only to VEGFR1. VEGF-C and VEGF-D bind to VEGFR2 and
VEGFR3 (for review see ref. 2).
VEGF-A has clearly emerged as the family member principally
responsible for normal vasculogenesis and HA. The direct effects
of VEGF-A on vascular endothelial cells are mediated principally
via VEGFR2 ligation, while, until recently, VEGFR1 was thought
to mediate mainly inhibitory or decoy functions (for review see
refs. 1, 2). VEGF-A also plays a predominant role in diverse forms
of pathological angiogenesis, including those requisite for the
rapid growth of solid tumors (for review see refs. 1, 2). For this rea-
son many antiangiogenic agents currently in development for the
treatment of cancers have targeted VEGF-A or VEGFR2 (for review
see refs. 2, 3; http://www.cancer.gov). 
In contrast to HA, lymphangiogenesis is thought to be mediat-
ed mainly by the binding of VEGF-C and -D to their high-affinity
receptor, VEGFR3 (for review see ref. 4). Like HA, lymphangio-
genesis has gained much attention recently as an important initial
step in tumor pathogenesis (for review see ref. 4; refs. 5–7). It has
been shown that intra- and/or peritumoral lymphangiogenesis
increases the risk for metastasis both in animal models and in
human tumors (for review see ref. 4). The release of the lymphan-
giogenic growth factors VEGF-C and -D has been linked to a cir-
culating subfraction of CD14+, VEGFR3-expressing monocytes
that are recruited to and activated at the site of tumor growth (8).
Antilymphangiogenic strategies targeting VEGFR3-mediated sig-
naling have been reported to inhibit lymphangiogenesis and
improve survival in animal models of metastatic cancer (5).
As noted above, VEGF-C and -D also bind to VEGFR2 and dis-
play hemangiogenic activities in certain situations (9,10). In
contrast, VEGF-A is thought to act solely as a hemangiogenic
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factor, as placement of VEGF-A–impregnated pellets in the
cornea (11), overexpression of VEGF-A in the skin (12–14), and
VEGF-A applied to the chorioallantoic membrane (15) have all
been reported to cause HA but not lymphangiogenesis. Howev-
er, it has recently been shown that, like blood endothelial cells,
lymphatic endothelial cells also express VEGFR2, and VEGF-A
potently promotes their survival in vitro (16–19). Moreover, ade-
noviral overexpression of VEGF-A in the rabbit ear leads to the
formation of hyperplastic, “giant” lymphatic vessels, further sug-
gesting that VEGF-A has the potential to stimulate some forms
of lymphangiogenesis (20).
As several antiangiogenic agents that target VEGF-A have already
entered clinical testing, the question of whether such agents might
also affect lymphangiogenesis has taken on particular importance
(4–7). In addition to promoting tumor metastases, induction of
lymphangiogenesis is also associated with the termination of the
immune-privileged state of the normally avascular cornea. The sig-
nificant deterioration of corneal transplant survival under these
conditions makes it imperative to determine whether antiangio-
genic strategies that target VEGF-A also interfere with corneal lym-
phangiogenesis (for review see ref. 21).
To address this question and to resolve conflicting findings
regarding the role of VEGF-A in lymphangiogenesis, we first char-
acterized a novel model of inflammatory neovascularization in the
cornea to determine whether HA is accompanied by lymphangio-
genesis (22, 23). We then evaluated the effect of selectively block-
ing the actions of endogenous VEGF-A (and PlGF) using VEGF
Trap (24) or of altering endogenous VEGF-A expression by using
transgenic mice that express only VEGF-A isoform 164 or 188
(VEGF-A164/164 or VEGF-A188/188, respectively) (25, 26). Finally, as
VEGF-A is known to recruit VEGFR1-expressing monocytes/
macrophages (27,28), which are known to release not only heman-
giogenic but also lymphangiogenic growth factors (8), and as
VEGF-mediated HA and lymphangiogenesis in our model was
accompanied by a marked inflammatory response, we evaluated (a)
systemic depletion of bone marrow–derived cells and (b) local
depletion of macrophages for their effects on lymphangiogenesis
and HA following corneal injury.
Methods
Mice and anesthesia. The generation of knock-in mice expressing
only VEGF-A isoform 164 or 188 on a Swiss Webster background
has been described previously (25, 26). BALB/c mice 6–8 weeks of
age were used in all experiments not involving knock-in mice
(Taconic Farms, Germantown, New York, USA). All mice exam-
ined were between 8 and 12 weeks of age and were treated in accor-
dance with the Association for Research in Vision and Ophthal-
mology Statement for the Use of Animals in Ophthalmic and
Vision Research. Mice were anesthetized using a mixture of
ketamine and xylazine (120 mg/kg body weight and 20 mg/kg
body weight, respectively).
Mouse model of suture-induced, inflammatory corneal neovascular-
ization. The mouse model of suture-induced inflammatory
corneal neovascularization (CNV) was used as previously
described (29). Briefly, a 2-mm-diameter corneal trephine was
placed gently on the central cornea of anesthetized mice solely
to mark the central corneal area. Three 11-0 sutures were then
placed intrastromally with two stromal incursions each extend-
ing over 120° of the corneal circumference. The outer point of
suture placement chosen was halfway between the limbus and
the line outlined by the 2-mm trephine; the inner suture point
was at the same distance from the 2-mm trephine line to obtain
standardized angiogenic responses. Sutures were left in place for
7 days. Mice were euthanized and the cornea with limbus was
excised, and flat-mount double-immunohistochemistry was per-
formed as described below.
Immunohistochemistry and morphometry of HA and lymphangiogenesis
in the cornea. Briefly, corneal flat mounts were rinsed in PBS, fixed
in acetone, rinsed in PBS, blocked in 2% BSA, stained with FITC-
conjugated CD31 (platelet–endothelial cell adhesion molecule 1
[PECAM-1]) antibody overnight (1:100 dilution; Santa Cruz
Biotechnology, Santa Cruz, California, USA), washed, blocked, and
stained with anti-LYVE-1 (1:500 dilution; LYVE-1 is a lymphatic
endothelium–specific hyaluronic acid receptor; D. Jackson, Oxford
University, Oxford, United Kingdom) (22, 30), which was visual-
ized using a indocarbocyanine-conjugated secondary antibody
(1:100 dilution; Jackson ImmunoResearch Laboratories, West-
grove, Pennsylvania, USA). Double-stained sections were analyzed
using a Zeiss Axiophot microscope. Digital pictures of the flat
mounts were obtained using the Spot Image Analysis system (Spec-
tra Services Inc., Webster, New York, USA), and the area covered by
CD31+++LYVE-1– blood vessels and CD31+LYVE-1+++ lymph vessels
(22, 23) (where +++ indicates strong positivity; ++, medium posi-
tivity; and +, mild positivity) was measured using NIH Image soft-
ware. The total corneal area was outlined using the innermost ves-
sel of the limbal arcade as the border, and the area of blood and
lymphatic neovascularization within the cornea was then calculat-
ed and normalized to the total corneal area (expressed as a per-
centage of the cornea covered by vessels). Paraffin embedding of
corneas and immunostaining for LYVE-1 and counterstaining with
hematoxylin and eosin was done as described previously (22).
Histological characterization and quantification of inflammatory cells
and immunohistochemistry for VEGF-C and VEGF-D. The presence of
inflammatory cells in normal corneas and their recruitment into
corneas 1 week after suture placement was quantified in hema-
toxylin and eosin–stained serial sections of plastic-embedded
corneas fixed in 10% paraformaldehyde after enucleation. In
addition, for further characterization of inflammatory cells
recruited to the cornea, double immunohistochemistry was per-
formed on corneal whole mounts and frozen sections with the
macrophage markers CD11b (Pharmingen, San Diego, Califor-
nia, USA), CD68 (Santa Cruz Biotechnology), and F4/80 (Caltec,
San Francisco, California, USA), the panleukocyte marker CD45
(Pharmingen) and the neutrophil marker GR1 (Pharmingen) as
described previously (22).
For identification of the intracorneal source of lymphangio-
genic growth factors VEGF-C and -D, double immunohisto-
chemistry for VEGF-C and -D (polyclonal antibody; 1:100 dilu-
tion; Santa Cruz Biotechnology) and the macrophage markers
mentioned above was performed on corneal whole mounts 48
hours after corneal suture placement with additional Fc blockade
(Santa Cruz Biotechnology). Sections were evaluated using con-
focal microscopy (Leica TCS – SP2 Confocal Laser Scanning
Microscope, Leica, Wetzlar, Germany).
Selective neutralization of VEGF-A and PlGF using VEGF traps. VEGF
TrapR1R2 is a fusion protein comprising portions of the extracellu-
lar domains of human VEGFR1 (IgG domain 2) and VEGFR2 (IgG
domain 3) coupled to the Fc portion of human IgG1 (Regeneron
Pharmaceuticals Inc, Tarrytown, New York, USA) (24), VEGF
TrapR1R2 selectively binds VEGF-A and PlGF but not VEGF-C/
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VEGF-D (see below). Mice received a single injection of VEGF
TrapR1R2 intraperitoneally at a dose of 12.5 mg/kg at time of
corneal injury. Control mice received an injection of human Fc
(12.5 mg/kg intraperitoneally). In one study, we used another Trap
(VEGF TrapR1/A40) that comprised only portions of VEGFR1 (IgG
domains 1–3) fused to Fc to completely obviate the possibility of
binding to VEGF-C and -D. As this construct exhibits reduced
bioavailability as well as lower affinity for binding of VEGF-A com-
pared with the VEGF TrapR1R2, it was administered at a dose of 25
mg/kg (intraperitoneally).
Biochemical characterization of binding of VEGF-A, -C, and -D to VEGF
TrapR1R2 and VEGF TrapR1/A40. The specificity of binding of VEGF
family members to various VEGF receptor chimeras was assessed
using Biacore (Biacore, Piscataway, New Jersey, USA). Protein A
(Pierce Biotechnology, Rockford, Illinois, USA) was amine-coupled
(2000 resonance units [RU]) onto CM5 chips on all flow cells, and
VEGF TrapR1R2 and VEGF TrapR1/A40 were captured onto the chip
surface at levels of 1,324 and 2,315 RU, respectively. VEGFR1-Fc,
VEGFR2-Fc, and VEGFR3-Fc (R&D Systems, Minneapolis, Min-
nesota, USA) were used as control proteins; these constructs com-
prise the full extracellular domain of the indicated human recep-
tor fused to human Fc and were captured on protein A–coated
chips at 530, 522 and 441 RU. A flow cell with only amine-coupled
protein A was used to allow subtraction of nonspecific binding. 
VEGF ligands (325 µl each) were injected at a rate of 10 µl/min
in HEPES saline buffer containing 0.1 mg/ml of BSA (Fluka,
Buchs, Switzerland). Human VEGF-C, human VEGF-D, and
mouse VEGF-D (all from R&D) were injected at a concentration of
200 nM each. Human VEGF-A165, human VEGF-A121 (Regeneron
Pharmaceuticals Inc.) and mouse PlGF-2 (R&D) were injected at a
concentration of 50 nM each. Two 1-minute pulses of 100 mM
H3PO4 were used to clean protein A surfaces, and receptor-Fc
chimeras were recaptured on the chip for each ligand evaluated.
Data were expressed as RU of specifically bound ligand per
femtomole of receptor fusion protein captured on the pro-
tein A surface.
Analysis of lymphangiogenic effects of VEGF-A and VEGF-C in
the corneal micropocket assay. The corneal micropocket assay
was performed as previously described (10). Briefly, corneal
micropockets were created using a modified von Graefe
knife, and a micropellet (0.4 × 0.4 mm) of sucrose alu-
minum sulfate coated with hydron polymer containing
200 ng of VEGF-A164 (R&D) or 200 ng of recombinant rat
VEGF-C as a positive control (RDI, Flanders, New Jersey,
USA) was implanted into each pocket. The pellet was posi-
tioned 0.6–0.8 mm from the limbus and the site was cov-
ered with antibiotic ointment (erythromycin) and was left
in place for 10 days (n > 10 mice each). Hemangiogenic and
lymphangiogenic responses were quantified as described
above using double immunostaining with CD31/LYVE-1.
The maximal extent of blood versus lymph vessel out-
growth between subjacent limbus and pellet was graded
semiquantitatively in four categories for both vessel types:
0, no outgrowth; 1, outgrowth less than 1/3 of the limbus-
pellet distance; 2, outgrowth between 1/3 and 2/3 of the
limbus-pellet distance; 3, vessel reaching pellet.
Systemic depletion of bone marrow–derived cells by γ-irradia-
tion of mice. BALB/c mice were pretreated with acidified
water for 3 days and then were exposed to a single dose of
9 Gy whole body γ-irradiation. After 18 hours, sutures
were placed into the corneas as described above. Control mice
received the acidified water pretreatment and suture placement.
Seven days later, the mice were euthanized and their corneas were
removed for flat-mount staining and morphometry as described
above (at least three mice per group per experiment). 
Local depletion of macrophages using subconjunctival clodronate lipo-
somes. Local depletion of monocytes/macrophages was accom-
plished as described previously (31, 32). Liposomes filled with
dichloromethylene diphosphonate (CL2MDP-LIP; 10 µl; a gener-
ous gift from Nico van Rooijen, Vrije Universiteit, Amsterdam,
The Netherlands) was injected subconjunctivally at the time of
suture placement and 2, 4, and 6 days after surgery. Control group
mice received either liposomes containing PBS or only PBS sub-
conjunctivally at the same time points. To rule out the possibility
of vascular endothelial uptake of clodronate liposomes and a
direct effect of clodronate on blood and lymphatic endothelium,
the effect of clodronate versus Fc protein injected subconjuncti-
vally on preexisting pathological corneal vessels (previously
induced by corneal suturing) and normal limbal vessels was
assessed 12 hours after injection.
Cultivation of bone marrow–derived macrophages. Bone marrow–
derived macrophages were harvested and cultured as previously
described (33). Briefly, BALB/c mice 6 weeks of age were eutha-
nized, their femur bones were dissected and cut at both ends,
and the bone marrow was flushed into HBSS (Cambrex Bio Sci-
ence, Verviers, Belgium) using a PBS-filled 25-gauge needle.
Then, the bone marrow cells were washed and resuspended in
growth medium consisting of DMEM (Sigma-Aldrich, St. Louis,
Missouri, USA) with 10% horse serum (Sigma-Aldrich), 10%
CPSR-1 (Sigma-Aldrich), 10% L929 cell–conditioned medium,
1% MEM vitamins (Invitrogen, Carlsbad, California, USA), 1%
sodium pyruvate (Cambrex), 1% NEAA (Cambrex), 1% L-glu-
tamine (Cambrex), and 1% penicillin/streptomycin (Cambrex).
Figure 1
Concomitant induction of HA and lymphangiogenesis in inflammatory corneal
neovascularization. (A–F) Seven days after central, intrastromal suture place-
ment (A), a robust angiogenic response (A; blood vessel [BV]) in combination
with an influx of inflammatory cells (B [H&E] and C) can be seen biomicroscop-
ically (A) and by using CD31 (PECAM1) immunostaining (D) of corneal flat
mounts (green). The CD45+ inflammatory cell infiltrate (C) consists mainly of 
GR-1+ neutrophils (red) and F4/80+ macrophages (green). In addition to the
CD31+++LYVE-1– blood vessels (D and E; green), there is parallel outgrowth of
CD31+LYVE-1+++ lymphatic vessels (LV; D–F; red). Blood vessels do not react
with the lymphatic vascular–specific hyaluronic acid receptor LYVE-1 (F). Mag-
nification, ×20 (A), ×200 (B and F), ×400 (C and E), and ×100 (D).
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After 7 days of culture, adherent cells were then processed for
RNA and RT-PCR as described above.
Statistical analysis. Statistical significance was analyzed by the Mann-
Whitney U test. Differences were considered significant at P < 0.05.
Each experiment was performed at least twice with similar results.
Graphs were drawn using Graph Pad Prism, Version 3.02 (Graph Pad
Software, San Diego, California, USA).
Results
Suture-induced, inflammatory CNV is characterized by HA, lymphangio-
genesis, and inflammatory cell infiltration. To address the question of
whether endogenous VEGF-A might be involved in lymphangio-
genesis, we first studied an established model of suture-induced
inflammatory CNV to evaluate the outgrowth of lymphatic vessels
into the normally avascular cornea (22, 29). This model is charac-
terized by a robust outgrowth of new blood vessels from the lim-
bal arcade (Figure 1, A–C) and is routinely used in the mouse to cre-
ate a vascularized “high-risk bed” for corneal transplantation
studies. New blood vessels reached the sutures at 1 week after
surgery and were accompanied by a dense inflammatory cell infil-
trate. CD45+ inflammatory cells within the corneal stroma mainly
consisted of GR-1+ neutrophils and, less prominently, also
F4/80+CD11b+ macrophages (Figure 1). To determine whether this
early HA was accompanied by lymphangiogenesis, corneal whole
mounts were double-stained using CD31 as a panendothelial
marker and LYVE-1 (22, 30) as specific lymphatic vessel marker.
One week after surgery, both CD31+LYVE-1+++ lymphatic vessels as
well as CD31+++LYVE-1– blood vessels grew into the cornea (Figure
1, D–F), demonstrating that a robust lymphangiogenesis is also
induced in this CNV model.
Blood and lymphatic vessels display rapid and parallel outgrowth in CNV.
Based on wound healing studies in skin, it has been suggested the
ingrowth of lymphatic vessels is delayed for several days relative to
that of blood vessels (34). To determine whether this holds true for
the CNV model, we conducted a time-course study comparing the
outgrowth of both vessel types. As is illustrated in Figure 2, HA and
lymphangiogenesis occurred contemporaneously. Small sprouts
arising from pre-existing limbal vessels could be detected as early
as 24 hours after surgery, and outgrowth of new vessels of both
types was clearly visible at 48 hours (Figure 2). Interestingly, lym-
phatic vessels sometimes grew in advance of blood vessels at the
leading edge of growth (Figure 2).
Figure 2
Time course of early inflammatory HA and lymphangiogenesis. (A–D)
In inflammatory corneal neovascularization, there is very early and par-
allel outgrowth of both blood vessels (green) as well as lymphatic ves-
sels (red) from the limbal vascular arcade (bottom of each picture)
toward the suture into the normally avascular cornea (top of each pic-
ture). Both vessel types sprout as early as 24 hours after injury and
progress over time, with lymphatic vessels (red staining) often preced-
ing blood vessels (green staining). Magnification, ×100.
Figure 3
Neutralization of VEGF-A inhibits HA and lymphangiogenesis. (A–F) A
molecular trap designed to bind VEGF-A (VEGF TrapR1R2) completely
inhibits both HA and lymphangiogenesis within 1 week after injury.
Whereas mice receiving an intraperitoneal injection of Fc protein at
surgery (Fc control) display robust angiogenesis (A, slit-lamp picture; B,
CD31 staining) and lymphangiogenesis (C, CD31 and LYVE-1 staining)
1 week later, mice treated with a single injection of VEGF TrapR1R2 do not
show HA (D and E; blood vessels are green) or lymphangiogenesis (F;
lymph vessels are red). Magnification, ×100 (C–F). (G) Morphometric
analysis of the nearly complete inhibitory effect of VEGF Trap on both
HA and lymphangiogenesis (P < 0.001). Magnification (A and B), ×20.
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Administration of VEGF TrapR1R2 completely inhibits HA and lymphan-
giogenesis in inflammatory CNV. To determine the extent to which
VEGF-A is important for inflammation-associated lymphangio-
genesis, we treated mice systemically with a molecular trap that
selectively binds and neutralizes VEGF-A but not VEGF-C or -D
(VEGF TrapR1R2). Administration of VEGF-TrapR1R2 completely
prevented both HA and lymphangiogenesis 7 days after suture
placement, as determined by examination of the corneas (Figure 3;
the area vascularized by blood and lymphatic vessels was 49% ± 12%
in Fc-treated mice and 2.3% ± 1.5% in mice treated with VEGF
TrapR1R2, P < 0.001). Moreover, examination of corneas at days 2, 4,
and 7 after suture placement revealed that blood and lymphatic
vessels never grew out from the limbus in the Trap-treated group.
Although in vitro binding studies showed that VEGF TrapR1R2
binds only VEGF-A and PlGF with high affinity, but not VEGF-C
or -D (see below), we further ruled out the possibility that the
observed response might be due to neutralization of VEGF-C and
-D in vivo by repeating the above experiment using VEGF
TrapR1/A40. Though it is less bioavailable and exhibits a lower affin-
ity for VEGF-A, this reagent consists only of the ligand-binding
domain of VEGFR1 but not VEGFR2, and thus it is inherently
incapable of binding VEGF-C or -D. Using this agent we observed
a similar parallel and significant, albeit less complete, inhibition of
both HA (53.8% ± 14.6% versus 23.6% ± 6.8%) and lymphangiogen-
esis (45.7% ± 15.6% versus 26% ± 8.2%; P < 0.05).
VEGF TrapR1R2 and TrapR1/A40 bind only VEGF-A and PlGF but not
VEGF-C/VEGF-D. When added to tissue cultures at approximately
equimolar concentrations, VEGF TrapR1R2 has been shown to block
VEGF-A–induced phosphorylation of VEGFR2 as well as prolifer-
ation of primary human umbilical vein endothelial cells (24). VEGF
TrapR1R2 binds VEGF165 with very high affinity (KD, ∼1 pM). Simi-
lar results have been obtained using murine VEGF164, and in pre-
liminary studies mouse PlGF was also found to bind to VEGF
TrapR1R2 with high affinity (KD, ∼1.8 pM). The results of Biacore
binding studies confirmed that both
VEGF TrapR1R2 and TrapR1/A40 selec-
tively bound VEGF-A (VEGF165 and
VEGF121) and PlGF, but there was no
detectable binding of VEGF-C or -D
to either VEGF Trap at concentra-
tions up to 200 nM (Figure 4 and
Table 1). VEGFR1-Fc demonstrated
the same pattern of binding to the
above VEGF family members. In
contrast, VEGFR3-Fc avidly bound
VEGF-C and -D but not PlGF or
either isoform of VEGF-A. Collec-
tively, these data clearly demonstrate
that VEGF TrapR1R2 and VEGF TrapR1/A40 bind only VEGF-A and
PlGF but not VEGF-C or -D, whereas VEGFR3-Fc binds only
VEGF-C and -D but not VEGF-A or PlGF.
Mice that express only VEGF-A188 or VEGF-A164 display significantly
reduced HA and lymphangiogenesis. To further evaluate the role of
VEGF-A in promoting lymphangiogenesis, we studied mice that
express only VEGF-A isoform 164 or 188. We hypothesized that
specific genetic deletion of VEGF-A isoforms should only affect
lymphangiogenesis if VEGF-A is involved in mediating lymphan-
giogenesis. Sutures were placed in the corneas; 1 week later,
VEGF164/164 mice (lacking VEGF-A isoforms 120 and 188) dis-
played an area of HA of 27.9% ± 12% and an area of lymphangio-
genesis of 22.7% ± 13.6%. Sutured corneas of VEGF188/188 trans-
genic animals (lacking VEGF-A isoforms 120 and 164) displayed
an area of HA of 20.3% ± 10% and an area of lymphangiogenesis of
25% ± 12.7%. These represent significant reductions in areas of
both lymphangiogenesis and HA compared with wild-type con-
trols (HA, 44% ± 10.2%; area of lymphangiogenesis, 57.2% ± 9.6%;
P < 0.05; Figure 5). Thus, both HA and lymphangiogenesis can
occur in the absence of VEGF-A isoforms 120 and 188 as well as
in the absence of isoforms 120 and 164. However, under these cir-
cumstances the extent of both corneal HA and lymphangiogene-
sis is equivalently diminished, suggesting that an orchestrated
action of VEGF-A isoforms is necessary for lymphangiogenesis. 
VEGF-A164 can induce lymphangiogenic as well as hemangio-
genic responses in the corneal micropocket assay. To determine
whether exogenous VEGF-A can exert a direct lymphangiogenic
effect, we studied the effect of VEGF-A164 in the corneal microp-
ocket assay. Lymphangiogenesis as well as HA was induced in 17 of
20 corneas that had been implanted with pellets (200 ng) of
VEGF-A. Lymphatic vessels were noted to be appreciably shorter
than the accompanying blood vessels (semiquantitative grading,
2.7 ± 0.7 versus 1 ± 0.9; P < 0.01; Figure 6). These findings indicate
that VEGF-A alone can induce lymphangiogenesis, although less
Figure 4
VEGF TrapR1R2 and VEGF TrapR1/A40 bind only VEGF-A/PlGF, not
VEGF-C/VEGF-D. Biacore biochemical evaluation of binding of VEGF/
PlGF growth factors to VEGF Traps and VEGF receptor chimeric pro-
teins (VEGFR1-Fc, VEGFR2-Fc, and VEGFR3-Fc), demonstrates that
VEGF TrapR1R2 and VEGF TrapR1/A40, used in this study, bind only
VEGF-A/PlGF, not VEGF-C or -D. In contrast, VEGF-C and -D, but not
VEGF-A/PlGF, bind to VEGFR3-Fc.
Table 1
VEGF TrapR1R2 and VEGF TrapR1/A40 selectively bind VEGF-A and PlGF, but not VEGF-C 
and VEFG-D
hVEGFA165 hVEGFA121 mPLGF hVEGFC hVEGFD mVEGFD Buffer
(50 nM) (50 nM) (50 nM) (200 nM) (200 nM) (200 nM) (BSA)
VEGF TrapR1R2 36.3 19.7 26.8 0 0 0 0
VEGF TrapR1/A40 40.9 22.6 34.6 0 0 0 0
VEGFR1-Fc 31.3 15.9 22.3 0 0 0 0
VEGFR2-Fc 30.1 14.1 0 0.8 2.1 2.1 0
VEGFR3-Fc 0 0 0 29.5 12.4 14.4 0
h, human; m, murine.
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robustly than HA. The same was found for VEGF-C pellets used as
controls. There was no significant difference in the ratio of HA ver-
sus lymphangiogenesis between VEGF-C and -A pellets (P = 0.8). 
VEGF TrapR1R2 significantly reduces the recruitment of inflammatory
cells into the cornea. Because VEGF is chemotactic for inflamma-
tory cells, for example, monocytes/macrophages via VEGFR1
(27, 28), and because macrophages can potentially secrete lym-
phangiogenic factors such as VEGF-C and -D (8, 35), we investi-
gated whether neutralization of VEGF-A using VEGF TrapR1R2
would also impair the recruitment of bone marrow–derived cells
into the cornea following suture injury. Animals that received a
single intraperitoneal injection of VEGF TrapR1R2 at time of
surgery exhibited significantly reduced numbers of stromal
inflammatory cells compared with controls (Figure 7); the num-
ber of inflammatory cells per corneal cross-section in VEGF
TrapR1R2–treated mice was 188 ± 14 compared with 909 ± 167 in
Fc-treated control mice (P < 0.01). The inflammatory infiltrate
in the Fc-treated controls was composed of GR-1+ neutrophils
and, less often, F4/80+ macrophages.
Depletion of bone marrow–derived cells by whole-body γ-irradiation
inhibits lymphangiogenesis. Macrophages can be recruited to sites of
inflammation by VEGF-A via VEGFR1 interactions (27, 28), and
activated macrophages are known to express a variety of cytokines
and growth factors, including VEGF-A, -C, and -D (8, 35). Since
the inhibition of corneal neovascularization by the VEGF TrapR1R2
was associated with a marked decrease in the recruitment of
inflammatory cells into the cornea, we determined whether deple-
tion of inflammatory cells by other means would also inhibit HA
and lymphangiogenesis following corneal injury. In preliminary
experiments we confirmed that whole-body irradiation with a sin-
gle dose of 9 Gy caused nearly complete depletion of leucocytes
from the peripheral blood within 1 week of irradiation (data not
shown). The results in Figure 8 show that depletion of bone mar-
row–derived cells by irradiation substantially inhibited both HA
and lymphangiogenesis in response to corneal inflammatory
stimuli. The areas of blood and lymphatic vessels in irradiated
mice were 18.4% ± 4% and 16.4% ± 3.2%, respectively, compared
with 49.6% ± 10.4% and 38% ± 12.23% for blood and lymph vessels,
respectively, in unirradiated controls (P < 0.05).
Local macrophage depletion inhibits corneal lymphangiogenesis. We next
evaluated the effect of selective macrophage depletion in the cornea
by subconjunctival injection of clodronate liposomes (31, 32).
Macrophages that phagocytose clodronate liposomes rapidly die.
Subconjunctival liposome injection on days 0, 2, 4, and 6 was
applied to eyes with centrally sutured corneas. Local depletion of
macrophages nearly completely inhibited corneal lymphangiogen-
esis and HA (Figure 9); the areas of blood and lymph vessels in mice
receiving clodronate were 11.3% ± 5.8% and 10.8% ± 2.5%, respec-
tively, compared with 42.3% ± 11.3% and 38.8% ± 4.7% for blood and
lymph vessels, respectively, in PBS-treated controls (P < 0.01). There
was no obvious direct effect of locally applied clodronate liposomes
on preexisting limbal and pathological corneal blood or lymphatic
vessels. These results demonstrate that macrophages, recruited to
the site of injury by ligation of VEGFR1, are critical to inflamma-
tion-associated HA and lymphangiogenesis.
Macrophages in inflamed corneas express lymphangiogenic
VEGF-C and -D. To directly assess whether macrophages recruited
Figure 5
Importance of VEGF-A isoforms for lymphangiogenesis. (A–E) Double
immunostaining CD31/LYVE-1 (blood vessels, green; lymphatic ves-
sels, red) of corneal flat mounts of wild-type mice (A), VEGF-A164/164
transgenic mice (B), and VEGF-A188/188 transgenic mice (C) demon-
strates significantly reduced HA (D; P < 0.05) and lymphangiogenesis
(E; P < 0.05). Magnification, ×100 (A–C).
Figure 6
Effect of VEGF-A on lymphangiogenesis in corneal micropocket
assay. (A–C) Pellets (*) containing 200 ng VEGF-A always
induced a robust hemangiogenic response (A, green; Li, limbal
vascular arcade [arrowhead]) and in 17 of 20 pellets in addition
there was a mild to moderate lymphangiogenic response (red),
which was significantly less compared with the hemangiogenic
response (B). Panel C shows a representative and comparable
effect by a VEGF-C pellet (200 ng). Magnification (A and C), ×100.
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by VEGF-A into inflamed corneas are able to release lymphangio-
genic growth factors VEGF-C and -D, we performed immunohis-
tochemical studies in inflamed corneas 48 hours after suture place-
ment using double labeling for VEGF-C/VEGF-D and the
macrophage markers CD11b and F4/80. As depicted in Figure 10,
this revealed that most CD11b+F4/80+ macrophages in the stroma
were positive for VEGF-C and some were also positive for VEGF-D.
To provide further support for the notion that mouse macro-
phages can express VEGF-C and -D, we performed RT-PCR studies
on cultivated bone marrow–derived mouse macrophages. As shown
in Figure 10, these macrophages were able to transcribe both
VEGF-C and -D mRNA.
Discussion
The results we have obtained in the corneal model of inflammatory
neovascularization allow two important conclusions to be drawn
regarding the role of VEGF-A in blood and lymphatic vessel growth.
First, endogenous VEGF-A can promote lymphangiogenesis, at least
in the context of inflammatory forms of neovascularization. Second,
signaling via VEGFR1 on leukocytes, particularly monocytes/
macrophages, is a critical step in “immune amplification” of signals
that promote pathological HA and lymphangiogenesis.
The present observations, that lymphangiogenesis and HA occur
contemporaneously in CNV and that both responses are equally
blocked by the selective inhibition of endogenous VEGF-A, appear
to contradict the established notion that the ligation of VEGF-A to
VEGFR2 induces solely HA, while interactions between VEGF-C/
VEGF-D and VEGFR3 discretely mediate lymphangiogenesis.
Indeed, a substantial literature supports this essential dichotomy
in the function of VEGF family proteins and their receptors. For
example, when applied to differentiated chick chorioallantoic
membrane (CAM), VEGF-A was found to stimulate HA, but not
lymphangiogenesis, while VEGF-C induced only lymphangiogen-
esis (15). Interestingly, the VEGFR1-selective ligand PlGF was
unable to induce either lymphangiogenesis or HA in the CAM
assay. Similarly, in the corneal micropocket assay, VEGF-A was
reported to induce HA but not lymphangiogenesis (11), and in sev-
eral studies using adenoviral overexpression, VEGF-C consistently
induced lymphangiogenesis, while VEGF-A did not (12–14). While
these studies do demonstrate that VEGF-C/VEGFR3 and VEGF-A/
VEGFR2 interactions can induce pure lymphangiogenic and
Figure 7
Anti-inflammatory effect of trapping VEGF-A. (A–C) Trapping of VEGF-A/
PlGF using the molecular cytokine trap VEGF TrapR1R2 significantly
reduces the recruitment of inflammatory cells into the cornea in the
suture-induced neovascularization model. One week after surgery, con-
trol mice treated with Fc protein (Fc control) displayed a significant influx
of inflammatory cells (IC and arrows) into the central corneal stroma
(A).Trapping of VEGF-A significantly reduces this influx (B; and C, nor-
mal cornea). (D) Trapping of VEGF-A reduces stromal inflammatory
cells by about 80% (P < 0.01). (E and F) The inflammatory cells found
in the corneal stroma 7 days after suture placement and Fc treatment
(controls) are overwhelmingly GR-1+ neutrophils (E, red) and less com-
monly, F4/80+CD11b+ macrophages (F, green). Magnification, ×100
(A–C) and ×400 (E and F).
Figure 8
Bone marrow–derived cells mediate inflammation-associated lym-
phangiogenesis. (A–C) Depletion of bone marrow–derived cells
induces a parallel inhibition of both HA and lymphangiogenesis in
response to corneal inflammatory stimuli (blood vessels, green; lym-
phatic vessels, red). (A) Seven days after suture placement, control
mice display parallel outgrowths of blood and lymphatic vessels from
the limbal vascular arcade (left). (B and C) A single whole-body irradi-
ation causes significant parallel inhibition of both HA and lymphangio-
genesis. Inset in B shows a representative area of a normal limbal vas-
cular arcade without vessel outgrowth. In C, controls are compared to
irradiated mice (S + Rx); P < 0.05. Magnification (A and B), ×100.
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hemangiogenic responses, respectively, under certain conditions,
more recent studies are beginning to show that this dichotomy
is far from complete.
In fact, VEGF-C and -D possess dual lymphangiogenic and
hemangiogenic properties (2, 9, 10, 36, 37), and VEGFR3, while
universally expressed by the lymphatic endothelium, is also
expressed by vascular endothelial cells under some conditions, par-
ticularly during embryonic development and periods of active ves-
sel remodeling, including that occurring in pathology (34, 37).
In contrast to VEGF-C and -D, there is comparatively little evi-
dence to support the notion that VEGF-A might be involved in
lymphangiogenesis. However, a recent molecular profiling study
has shown that lymphatic endothelial cells can express VEGFR2
and that VEGF-A is as effective as VEGF-C in supporting their sur-
vival and promoting tube formation in vitro (16–19). Another
recent study has demonstrated that adenoviral overexpression of
VEGF-A164 in the rabbit ear leads to the formation of “giant” lym-
phatic vessels (20). These studies raised the possibility that
endogenous VEGF-A might, under some circumstances, play a
role in promoting lymphangiogenesis — a possibility that we have
confirmed in the present studies.
Specifically, we have demonstrated that (a) exogenous VEGF-A
alone can induce lymphangiogenesis in the corneal pocket assay
(different findings in a previous study [ref. 11] might be explained
by the use of different mouse strains, amounts of VEGF-A and
staining techniques); (b) lymphangiogenesis and HA occur con-
temporaneously in a corneal injury model of inflammatory neo-
vascularization; (c) selective pharmacological neutralization of
VEGF-A/PlGF completely inhibited both HA and lymphangiogen-
esis in this model due to primary inhibition of blood and lym-
phatic vessel formation rather than via accelerated regression; and
(d) following corneal injury, both lymphangiogenesis and HA were
equivalently reduced in transgenic mice that expressed only either
VEGF-A164 or VEGF-A188 (25, 26). Taken together, these results
demonstrate that endogenous VEGF-A plays a critical role in pro-
moting lymphangiogenesis as well as HA, at least under certain
pathophysiological conditions.
We next turned our attention to mechanisms that might
explain the coordinate induction of HA and lymphangiogenesis
in this model and the effective suppression of both responses by
selective inhibition of VEGF-A. Here we noted that in addition to
suppressing CNV, administration of VEGF Trap also significant-
ly suppressed the inflammatory response that is induced by the
placement of intrastromal corneal sutures. It is well established
that VEGF-A is a potent monocyte chemoattractant and that this
effect is mediated by ligation of VEGFR1 (27, 38, 39). Thus, one
likely scenario is that VEGF-A indirectly stimulates lymphangio-
genesis in CNV by recruiting bone marrow–derived cells, partic-
ularly monocytes/macrophages, to the affected site and these
cells in turn are the source of one or more lymphangiogenic fac-
tors. Activated leucocytes are know to express and secrete a large
number of cytokines and other regulatory peptides and proteins,
including VEGF-A (31, 40, 41). Moreover, it has recently beenFigure 9
Macrophages are essential for pathological HA and lymphangiogen-
esis. (A and C) PBS-treated controls. (B and D) Mice that received
subconjunctival clodronate liposomes. Magnification, ×100 (C and D).
(E) Depletion of macrophages inhibits both HA and lymphangiogen-
esis (LA) in inflammatory neovascularization (P < 0.01). Magnification
(A and B), ×20.
Figure 10
Macrophages in inflamed corneas express both VEGF-C and -D.
(A) Cultivated, bone marrow–derived macrophages from BALB/c mice
transcribe VEGF-C and -D mRNA 1 week after seeding. 1, VEGF-C
positive control; 2, mouse bone marrow–derived macrophage VEGF-C;
3, VEGF-D positive control; 4: mouse bone marrow–derived macro-
phage VEGF-D. (B) Expression of VEGF-C (green) in red-stained
CD11b+ macrophages in an inflamed cornea 48 hours after injury.
(C) Expression of VEGF-D (green) in red-stained CD11b+ macrophages
in an inflamed cornea 48 hours after injury.Arrows indicate a represen-
tative macrophage. Magnification (B and C), ×600.
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shown that a subfraction of circulating VEGFR3+CD14+ mono-
cytes also strongly expresses VEGF-C and VEGF-D upon recruit-
ment to peritumoral sites or in vitro stimulation (8). Moreover,
VEGF-C+ macrophages colocalize with new peritumoral lymph
vessels, strongly suggesting a role for these cells in lymphangio-
genesis (8, 42). Furthermore, it is known that proinflammatory
cytokines, rather than hypoxia, upregulate VEGF-C expression
(43) and that VEGF-C consequently is highly expressed in inflam-
matory conditions (44) suggesting even more strongly that
VEGF-A–recruited macrophages upregulate VEGF-C/VEGF-D in
response to corneal inflammatory cytokines. Indeed we have
demonstrated here that CD11b+F4/80+ macrophages in the
inflamed corneal stroma express VEGF-C (more than VEGF-D)
and that bone marrow–derived mouse macrophages transcribe
both VEGF-C and -D mRNA.
The results of the present study directly support the concept
that VEGF-A–mediated recruitment of inflammatory cells by
VEGFR1 ligation is an important step in the initiation of the lym-
phangiogenic response in CNV. Pharmacological neutralization
of VEGF-A significantly inhibited recruitment of inflammatory
cells into the cornea after suture placement. Moreover, systemic
depletion of bone marrow–derived cells by irradiation signifi-
cantly attenuated corneal lymphangiogenesis after an inflam-
matory stimulus. Furthermore, local depletion of macrophages
using subconjunctival clodronate liposomes substantially inhib-
ited lymphangiogenesis. Finally, macrophages in inflamed
corneas expressed both lymphangiogenic VEGF-C and -D. Taken
together, these findings provide strong evidence that macrophage
recruitment is an essential mediator of the (indirect) lymphan-
giogenic effect of VEGF-A (Figure 11 depicts this concept). Here
it is also important to note that macrophage depletion not only
suppressed lymphangiogenesis following corneal injury but also
effectively suppressed concomitant HA. This observation is con-
sistent with a previous study showing that selective macrophage
depletion inhibits pathological neovascularization in other dis-
ease models (45), supporting the notion that inflammation is
also a requisite component of pathological HA mediated by
VEGF-A (45, 46).
While VEGF-mediated recruitment of inflammatory cells
clearly plays an important and apparently predominant role in
promoting pathological neovascularization, it is quite likely that
other, more direct actions of VEGF-A contribute to initiating
both hemangiogenic and lymphangiogenic responses. For exam-
ple, VEGF-A acts directly on vascular endothelium to upregulate
the expression of adhesion molecules that promote leukostasis
(47, 48). Likewise, rapid VEGF-mediated increases in the perme-
ability of resident vessels and the consequent extravasation of
serum proteins also serve to promote the subsequent formation
of both blood and lymphatic vessels (17, 49). It is also possible
that VEGF-A acts directly on VEGFR2 to promote the growth
and organization of the lymphatic endothelium (16, 50). Final-
ly, in addition to recruiting inflammatory cells that supply
cytokines and growth factors to the site of injury, VEGF-A may
also amplify angiogenic responses by recruiting VEGFR1-posi-
tive hematopoietic progenitor cells to the affected site and pro-
moting their differentiation into vascular endothelium (for
review see refs. 2, 51).
While our data strongly support the concept that recruitment
of monocytes/macrophages by VEGF-A, through VEGFR1, is an
early and essential step in an immune amplification cascade that
leads to both inflammatory HA and lymphangiogenesis (see Fig-
ure 11), it is formally possible that the VEGFR1 ligand PlGF
could also be partly responsible for promoting both corneal HA
and lymphangiogenesis. Indeed, both VEGF TrapR1R2 and VEGF
TrapR1/A40 bind PlGF as well as VEGF-A. Although results of
other studies indicate that PlGF can collaborate with VEGF-A
in the stimulation of pathological HA (51, 52), three facts “argue
against” the possibility that endogenous PlGF plays a significant
role in promoting inflammatory lymphangiogenesis: (a) PlGF
binds only to VEGFR1, while the lymphatic endothelium
expresses only VEGFR2 and VEGFR3 (53); (b) overexpression of
AD-PlGF in the rabbit ear resulted in the formation of blood
vessels, but in contrast to VEGF-A it did not cause lymphangio-
genesis (20); and (c) in the present study, both lymphangiogen-
esis and HA were comparably reduced in VEGF-A isoform–defi-
cient transgenic mice.
Currently, the most parsimonious mechanistic explanation for
VEGF-A–mediated lymphangiogenesis in CNV is that VEGF-A pro-
motes this response indirectly by binding to VEGFR1 and recruit-
ing macrophages that secrete VEGF-C and/or VEGF-D at the site
of injury. However, in a previous study, application of an exogenous
VEGF-C isoform (156S) was unable to induce lymphangiogenesis
in the cornea micropocket assay (in contrast, e.g., to the skin) (11,
54). Thus, while there is evidence that VEGFR3 signaling is neces-
sary for corneal lymphangiogenesis (11), the hypothesis that
VEGFR3-signalling is sufficient for the initiation of corneal lym-
phangiogenesis awaits experimental confirmation. 
Inflammation is a common feature of diverse conditions char-
acterized by pathological neovascularization, so it is quite possi-
ble that VEGF-A may play an important role in promoting lym-
phangiogenesis as well as abnormal HA in other disease states
Figure 11
Proposed concept of an (indirect) lymphangiogenic role of VEGF-A via
recruitment of bone marrow–derived macrophages, which in turn can
release both hemangiogenic and lymphangiogenic growth factors.
Macrophages seem to be important for immune amplification, leading
to pathological HA and lymphangiogenesis.
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(42). If so, the present findings may have important ramifications
for “antiangiogenesis” therapies currently in development for the
treatment of a variety of diseases. As previously noted, a strong
correlation exists between the degree of peritumoral inflamma-
tion and lymphangiogenesis in diverse types of human tumors
(42). VEGF-A is highly expressed in most solid tumors and might
serve to amplify lymphangiogenesis as well as HA in cancers by
recruiting “lymphangiogenic” monocytes/macrophages. Thus,
antiangiogenic strategies that target VEGF-A signaling might also
prove effective in at least partially suppressing peritumoral lym-
phangiogenesis. In the context of corneal transplant rejection,
recruitment of antigen-presenting cells into afferent lymphatic
vessels is an essential step in the process by which the host
immune response emerges to foreign transplant antigens. Thera-
peutic strategies aimed at suppressing newly outgrowing lym-
phatics should improve transplant survival by inhibiting allosen-
sitization (C. Cursiefen and J.W. Streilein, unpublished
observations). As immune rejection is the most important cause
of corneal graft failure, our findings suggest that effective
inhibitors of VEGF-A signaling have the potential to improve the
survival of corneal transplants.
Note added in proof. J. Wayne Streilein is deceased.
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